Xing Yinghao, Li Pei, Jia Yuanyuan, Zhang Kexin, Liu Ming, Jiang Jingjing
Department of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang, China.
Front Aging Neurosci. 2023 Jan 12;14:1082575. doi: 10.3389/fnagi.2022.1082575. eCollection 2022.
Chronic systemic inflammation may be associated with neurocognitive decline, but the relationships between inflammatory bowel disease and related medications and the risk of Alzheimer's disease remain unclear.
We performed a meta-analysis to evaluate the associations of ulcerative colitis, Crohn's disease and related medications with risk of Alzheimer's disease. We identified cohort and case-control studies by searching PubMed, Embase and Web of Science up to August 2022.
Seven eligible studies with 20,174 cases of Alzheimer's disease were included in the meta-analysis. Six studies reported the association between ulcerative colitis and risk of Alzheimer's disease; five studies reported the association between Crohn's disease and risk of Alzheimer's disease. Meta-analysis combining these studies did not reveal any significant association of ulcerative colitis or Crohn's disease with risk of Alzheimer's disease. The pooled relative risks were 1.16 (95%CI: 0.96, 1.41) and 1.17 (95%CI: 0.84, 1.62) for ulcerative colitis and Crohn's disease, respectively. High heterogeneity was detected across the studies. Of note, there was an inverse association between inflammatory bowel disease related medication exposure and risk of Alzheimer's disease. The pooled relative risk of three studies for Alzheimer's disease was 0.86 (95%CI: 0.75, 0.99). No publication bias was detected.
This study does not support the association of ulcerative colitis and Crohn's disease with the risk of Alzheimer's disease. However, medications for the treatment of inflammatory bowel disease might be associated with a lower risk of Alzheimer's disease.
慢性全身性炎症可能与神经认知功能下降有关，但炎症性肠病及其相关药物与阿尔茨海默病风险之间的关系仍不明确。
我们进行了一项荟萃分析，以评估溃疡性结肠炎、克罗恩病及其相关药物与阿尔茨海默病风险的关联。我们通过检索截至2022年8月的PubMed、Embase和Web of Science确定了队列研究和病例对照研究。
荟萃分析纳入了7项符合条件的研究，共20174例阿尔茨海默病病例。6项研究报告了溃疡性结肠炎与阿尔茨海默病风险之间的关联；5项研究报告了克罗恩病与阿尔茨海默病风险之间的关联。对这些研究进行的荟萃分析未发现溃疡性结肠炎或克罗恩病与阿尔茨海默病风险有任何显著关联。溃疡性结肠炎和克罗恩病的合并相对风险分别为1.16（95%CI：0.96，1.41）和1.17（95%CI：0.84，1.62）。各研究间检测到高度异质性。值得注意的是，炎症性肠病相关药物暴露与阿尔茨海默病风险之间存在负相关。三项研究中阿尔茨海默病的合并相对风险为0.86（95%CI：0.75，0.99）。未检测到发表偏倚。
本研究不支持溃疡性结肠炎和克罗恩病与阿尔茨海默病风险相关。然而，用于治疗炎症性肠病的药物可能与较低的阿尔茨海默病风险相关。
